|
|
Duggingerstrasse 23 Reinach, CH 4143 Switzerland phone:(41) 61 417 9660 fax:(41) 61 417 9661
|
|
| Symbol |
ARPN |
| Exchange |
SWX |
| Founded |
0 |
| Employees |
|
|
|
| www.arpida.ch
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Products for the treatment of severe bacterial infections. |
 |
| Management |
| Dr. Jrgen Raths, President & CEO; Harry Welten, MBA, Senior VP & CFO; Dr. Andr Lamotte, Chairman; Dr. Hans Fnfschilling, Vice-Chairman; Prof. Axel Kleemann, Michel Pettigrew, MBA, Elmar Schnee, Dr. Matthias Staehelin, |
| |
|
|
|
|
|
|
|
| Keywords |
| woundwound, woundcare |
|
|
|
| Description |
|
Arpida focuses on the discovery and development of novel products for the treatment of severe bacterial infections. Arpida's leading product candidate is a broad-spectrum antibiotic which targets severe bacterial infections requiring hospital treatment and which are resistant to most current therapies. |
 |
 |
|
|
|
|
|
|